Kala Pharmaceuticals (KALA) Upgraded to Hold at BidaskClub

Kala Pharmaceuticals (NASDAQ:KALA) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, February 16th.

Other research analysts have also recently issued research reports about the company. Wedbush reiterated a “buy” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. JPMorgan Chase & Co. set a $35.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $35.80.

Kala Pharmaceuticals (NASDAQ KALA) traded up $0.22 during trading on Friday, hitting $16.85. The stock had a trading volume of 210,321 shares, compared to its average volume of 401,759. Kala Pharmaceuticals has a twelve month low of $11.81 and a twelve month high of $26.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00.

In other news, major shareholder Orbimed Advisors Llc acquired 362,240 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were bought at an average cost of $15.00 per share, for a total transaction of $5,433,600.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have purchased 1,108,150 shares of company stock worth $15,772,394 over the last quarter.

Several large investors have recently made changes to their positions in KALA. Victory Capital Management Inc. purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at about $12,414,000. Bank of New York Mellon Corp acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $540,000. Commonwealth Equity Services Inc acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $360,000. EAM Investors LLC acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $1,353,000. Finally, American International Group Inc. acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter worth approximately $122,000. Institutional investors and hedge funds own 72.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Kala Pharmaceuticals (KALA) Upgraded to Hold at BidaskClub” was originally posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.equitiesfocus.com/2018/03/14/kala-pharmaceuticals-kala-stock-rating-upgraded-by-bidaskclub.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply